Bokf Na Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Bokf Na cut its stake in Zoetis Inc. (NYSE:ZTS) by 8.8% in the second quarter, HoldingsChannel reports. The institutional investor owned 55,461 shares of the company’s stock after selling 5,331 shares during the quarter. Bokf Na’s holdings in Zoetis were worth $9,615,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. International Assets Investment Management LLC grew its stake in Zoetis by 40.7% in the 4th quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock valued at $479,000 after acquiring an additional 703 shares during the last quarter. Aveo Capital Partners LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $225,000. Gryphon Financial Partners LLC increased its stake in shares of Zoetis by 11.8% during the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after purchasing an additional 322 shares in the last quarter. Jump Financial LLC acquired a new position in shares of Zoetis during the 4th quarter worth approximately $339,000. Finally, Avantax Advisory Services Inc. lifted its stake in Zoetis by 7.4% in the 4th quarter. Avantax Advisory Services Inc. now owns 9,627 shares of the company’s stock valued at $1,900,000 after buying an additional 662 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $190.71 on Friday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The company has a market cap of $86.40 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 2.91 and a beta of 0.88. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a 50 day moving average price of $182.52 and a 200 day moving average price of $174.54.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the prior year, the firm posted $1.41 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. Sell-side analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current year.

Analyst Ratings Changes

ZTS has been the subject of a number of analyst reports. BTIG Research boosted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler boosted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus reiterated a “buy” rating and set a $200.00 price target on shares of Zoetis in a report on Tuesday, August 27th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.